Mar Vista Investment Partners LLC decreased its position in shares of Allergan PLC. (NYSE:AGN) by 72.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 129,229 shares of the company’s stock after selling 345,694 shares during the quarter. Mar Vista Investment Partners LLC’s holdings in Allergan PLC. were worth $26,485,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Honeywell International Inc. boosted its position in shares of Allergan PLC. by 13.6% during the 2nd quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock valued at $40,871,000 after acquiring an additional 20,100 shares during the last quarter. Sumitomo Life Insurance Co. boosted its position in shares of Allergan PLC. by 39.0% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 15,122 shares of the company’s stock valued at $3,099,000 after acquiring an additional 4,244 shares during the last quarter. Colony Group LLC boosted its position in shares of Allergan PLC. by 9.9% during the 2nd quarter. Colony Group LLC now owns 39,802 shares of the company’s stock valued at $9,675,000 after acquiring an additional 3,577 shares during the last quarter. Palladium Partners LLC boosted its position in shares of Allergan PLC. by 1.7% during the 2nd quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock valued at $7,575,000 after acquiring an additional 523 shares during the last quarter. Finally, Clear Harbor Asset Management LLC boosted its position in shares of Allergan PLC. by 67.7% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 5,039 shares of the company’s stock valued at $1,033,000 after acquiring an additional 2,035 shares during the last quarter. 81.21% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Allergan PLC. (NYSE:AGN) traded up $1.40 on Thursday, reaching $174.45. The company had a trading volume of 1,119,123 shares, compared to its average volume of 2,912,249. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. The firm has a market capitalization of $57,550.00, a P/E ratio of 11.14, a price-to-earnings-growth ratio of 1.09 and a beta of 1.12. Allergan PLC. has a 52-week low of $169.61 and a 52-week high of $256.80.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company posted $3.32 earnings per share. equities research analysts predict that Allergan PLC. will post 16.28 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 1.61%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s dividend payout ratio (DPR) is -12.39%.

Allergan PLC. declared that its Board of Directors has initiated a share buyback plan on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: “Mar Vista Investment Partners LLC Sells 345,694 Shares of Allergan PLC. (AGN)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/16/mar-vista-investment-partners-llc-sells-345694-shares-of-allergan-plc-agn.html.

Several brokerages have recently weighed in on AGN. UBS AG reissued an “outperform” rating and set a $275.00 price target on shares of Allergan PLC. in a research report on Wednesday, August 9th. BidaskClub lowered shares of Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Wells Fargo & Company restated an “outperform” rating and issued a $280.00 price objective (up from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Argus restated a “buy” rating and issued a $280.00 price objective on shares of Allergan PLC. in a report on Monday, August 14th. Finally, Cantor Fitzgerald restated a “hold” rating on shares of Allergan PLC. in a report on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $246.73.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.